Aryx Therapeutics I
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the tre… Read more
Market Cap & Net Worth: Aryx Therapeutics I (ARYX)
Aryx Therapeutics I (PINK:ARYX) has a market capitalization of $16.73K ($16.73K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #50879 globally and #15613 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aryx Therapeutics I's stock price $0.00 by its total outstanding shares 33461975 (33.46 Million).
Aryx Therapeutics I Market Cap History: 2015 to 2025
Aryx Therapeutics I's market capitalization history from 2015 to 2025. Data shows change from $63.58K to $16.73K (-18.07% CAGR).
Aryx Therapeutics I Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aryx Therapeutics I's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ARYX by Market Capitalization
Companies near Aryx Therapeutics I in the global market cap rankings as of March 19, 2026.
Key companies related to Aryx Therapeutics I by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Aryx Therapeutics I Historical Marketcap From 2015 to 2025
Between 2015 and today, Aryx Therapeutics I's market cap moved from $63.58K to $ 16.73K, with a yearly change of -18.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $16.73K | 0.00% |
| 2024 | $16.73K | 0.00% |
| 2023 | $16.73K | 0.00% |
| 2022 | $16.73K | -78.26% |
| 2021 | $76.96K | -57.41% |
| 2020 | $180.69K | +145.45% |
| 2019 | $73.62K | +100.00% |
| 2018 | $36.81K | -87.78% |
| 2017 | $301.16K | +80.00% |
| 2016 | $167.31K | +163.16% |
| 2015 | $63.58K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Aryx Therapeutics I was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.73K USD |
| MoneyControl | $16.73K USD |
| MarketWatch | $16.73K USD |
| marketcap.company | $16.73K USD |
| Reuters | $16.73K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.